Mandate

Skandia Investment and Investor Growth Capital acquire Swedish Orphan International

May 12, 2005

A consortium comprising of Investor Growth Capital (IGC), Skandia Investment (SI), the Swedish private equity firms and the CEO of Swedish Orphan International AB (SOI) have agreed to acquire the company. SOI is a Sweden based company with the business concept to develop, register, market and distribute orphan drugs, which are pharmaceuticals used in the treatment of rare disorders, for an undisclosed sum.

Vinge acted for Investor Growth Capital and Skandia Investment.
Ulf Sallnäs (responsible partner)
Helena Dandenell, Kristoffer Persson (associates)

Related

Vinge has advised Skeptiva AB in connection with its financing round

Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026

Vinge represents Studsvik AB (publ) in the acquisition of Kärnfull Next AB

Vinge has represented Studsvik AB (publ) in connection with the acquisition of Kärnfull Next AB, a company developing methods for building small modular nuclear reactors.
March 10, 2026